AP NEWS

CRISPR Therapeutics to Participate in Three June Conferences

June 5, 2018

ZUG, Switzerland and CAMBRIDGE, Mass., June 05, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to present at three conferences in June 2018.

The 2018 BIO International Convention Panel: Advances in Genome Editing – The Next Frontier in Human HealthDate: Wednesday, June 6, 2018Presentation: 1:45 – 2:45 PM ESTLocation: Room 210 B, Level 2, Boston Convention and Exhibition Center

Goldman Sachs 39th Annual Global Healthcare ConferenceDate: Wednesday, June 13, 2018Fireside Chat: 8:00 – 8:35 AM PSTLocation: Terranea Resort, Rancho Palos Verdes, CA.

The JMP 2018 Securities Life Sciences ConferencePanel: Gene Editing: From Science to RealityDate: Wednesday, June 20, 2018Presentation: 8:00 – 8:50 AM ESTLocation: The St. Regis Hotel, New York, NY

About CRISPR TherapeuticsCRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. The Company has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer AG and Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in London, United Kingdom. For more information, please visit www.crisprtx.com.

MEDIA CONTACT:Jennifer PaganelliWCG on behalf of CRISPR+1 347-658-8290 jpaganelli@wcgworld.com

INVESTOR CONTACT:Chris Erdman+1 617.307.7227 chris.erdman@crisprtx.com

Chris BrinzeyWestwicke Partners for CRISPR+1 339-970-2843 chris.brinzey@westwicke.com

AP RADIO
Update hourly